Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis - Wikidata - awgldk - TriplyDB

Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis

Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis

http://www.wikidata.org/entity/Q24628361

about

The metabolic vascular syndrome - guide to an individualized treatment Pediatric Statin Administration: Navigating a Frontier with Limited Data Population-based screening for cancer: hope and hype.Do physician communication skills influence screening mammography utilization?Statins: Can we advocate them for primary prevention of heart disease?Drug repurposing screen reveals FDA-approved inhibitors of human HMG-CoA reductase and isoprenoid synthesis that block Cryptosporidium parvum growth Learning lessons from operational research in infectious diseases: can the same model be used for noncommunicable diseases in developing countries?Statin use in patients with cirrhosis: a retrospective cohort study.Red yeast rice lowers cholesterol in physicians - a double blind, placebo controlled randomized trial.Cost-effectiveness of coronary artery calcium testing for coronary heart and cardiovascular disease risk prediction to guide statin allocation: the Multi-Ethnic Study of Atherosclerosis (MESA).Cost-effectiveness of the use of low- and high-potency statins in people at low cardiovascular risk The efficacy and cost-effectiveness of statins in low-risk patients.Statins and Cardiovascular Primary Prevention in CKD: A Meta-Analysis.The clinical benefit of implementing guidelines in cardiovascular disease prevention in real world settings.Clinical review: Statins and trauma--a systematic review.Performance of breast cancer screening methods and modality among Chinese women: a report from a society-based breast screening program (SBSP) in Shanghai The decline effect in cardiovascular medicine: is the effect of cardiovascular medicine and stent on cardiovascular events decline over the years?A healthier approach to clinical trials evaluating resveratrol for primary prevention of age‐related diseases in healthy populations.Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association.Acute kidney injury in statin initiators.Statins and beyond: concurrent strategies for prevention of cardiovascular disease in patients with type 2 diabetes.Pediatric pharmacogenomics: a systematic assessment of ontogeny and genetic variation to guide the design of statin studies in children.The relationship between statins and depression: a review of the literature.Primary prevention of cardiovascular events in patients with major mental illness: a possible role for statins.Statin intolerance: diagnosis and remedies.Statins for Primary Prevention of Cardiovascular Disease in Elderly Patients: Systematic Review and Meta-Analysis.Acute myocardial infarction and influenza: a meta-analysis of case-control studies.Meta-Analyses of Statin Therapy for Primary Prevention Do Not Answer Key Questions: An Empirical Appraisal of 5 Years of Statin Meta-Analyses.Statins for primary prevention.The Impact of US FDA and Health Canada Warnings Related to the Safety of High-dose Simvastatin.Evaluating wait times from screening to breast cancer diagnosis among women undergoing organised assessment vs usual care.Reporting bias in the literature on the associations of health-related behaviors and statins with cardiovascular disease and all-cause mortality.

P2860

Q26767142-866FEA10-497D-414C-9539-4BF3FB586A4F Q28068014-84BFF43C-1072-4814-941F-AAE7609D7C84 Q30251601-9CD8BEA5-3F67-44B9-8454-A254BF179784 Q34351661-9F7554E5-9DA0-4752-B543-F6A415A22598 Q34425102-D172C9DC-9BCE-4902-BA11-280283AD9BD2 Q34574121-A9163313-D5CD-4173-A9E3-9B706D12B0F8 Q34656807-5024BA80-7702-483B-B26F-F7A5FEAC6DB6 Q34661975-C3BA2311-02D4-4F7A-A570-B8338CFEF262 Q34834399-742B9DEE-E816-49D7-B786-5C213CC9C4D8 Q35191897-EBB1C82F-2769-4BF0-8326-B1C08112EDF1 Q35551084-6BB7E156-EBA9-4482-ABA2-7743583F004A Q35551124-5675F8E0-D351-4151-B04E-69D091824E7C Q35576102-5110279A-8575-4018-8018-99413808F2EF Q35843906-2E691016-300F-46E6-BFE8-FEF3E4E3519B Q36998040-E60FF759-39D9-4FCC-8194-8189422688AB Q37049137-E3608D2A-B613-4417-AA2E-342FD290DB75 Q37098181-05939715-CF3D-4833-9E41-EFDBBB0AD791 Q37152779-A856E20F-8F9D-4BAC-8C09-3D12FB9CE7DA Q37251490-948E5454-A67D-492C-8075-8DA5309E7E33 Q37293690-8E09B954-6A94-4C2D-817A-4855A2BB6206 Q38020453-17A5FFFA-2332-42A2-A157-5453ED9883E2 Q38049379-F34C6BDD-C6CC-448B-A13F-6965B92F5A6B Q38114474-6F3FC766-56C4-4FA5-8E3F-EC28772FCFFC Q38151984-ED5828A3-1521-4B88-A602-D1CE84A84A7E Q38430744-32AB3D10-8FE6-41A5-9FE4-C6365F346667 Q38561391-06165573-2B31-4ABD-9B48-5BE22A859F41 Q38574447-07A040CB-3256-481C-A745-D8A5EC4ABA40 Q40769604-46F8E89A-64B0-4152-9610-19EBF906AAAD Q42541891-36045B59-091D-45CF-A7AD-056CDB1F5256 Q47110995-6FE022B0-4B62-4B72-ADFB-E6F25241543A Q50763376-51C58530-6757-4D1D-8FD1-91F4620E18F0 Q55425023-A9C0BE31-41E0-4F7A-B5DB-5D68051400B2

P2860

Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis

http://www.wikidata.org/entity/Q24628361

description

2011 nî lūn-bûn

@nan

2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Efficacy of statins for primar ...... vascular risk: a meta-analysis

@ast

Efficacy of statins for primar ...... vascular risk: a meta-analysis

@en

Efficacy of statins for primar ...... vascular risk: a meta-analysis

@nl

type

label

Efficacy of statins for primar ...... vascular risk: a meta-analysis

@ast

Efficacy of statins for primar ...... vascular risk: a meta-analysis

@en

Efficacy of statins for primar ...... vascular risk: a meta-analysis

@nl

prefLabel

Efficacy of statins for primar ...... vascular risk: a meta-analysis

@ast

Efficacy of statins for primar ...... vascular risk: a meta-analysis

@en

Efficacy of statins for primar ...... vascular risk: a meta-analysis

@nl

P1433

Q24628361-65C3FD4C-9499-48A7-B8EF-2FA19FFF7245

P1476

Q24628361-46BD83D6-9302-4CF8-8755-A538851573B5

P2093

Q24628361-6C85FB5F-08DB-4221-800E-3CDCB505C6D1

Q24628361-984866D9-A13E-498C-924C-755D1DA62169

Q24628361-99A42132-A208-416B-9AFB-1D72A40AF3F3

Q24628361-BEFAB869-EFED-4163-997B-124AE386A81E

Q24628361-C31A1018-ACD3-46A7-88F1-62D88421E18C

Q24628361-E34252A8-B1E6-42EC-A4E3-77AD72269B3F

Q24628361-F90CCDF3-6F1F-41D6-B9E0-5E55A44AD2D2

P2860

Q24628361-01054497-7DD9-4C0F-8DA4-BCC3E2DB21C6

Q24628361-0857E225-387E-482D-ACB8-5799D62E978B

Q24628361-091BCE59-E376-4056-8F30-72EF1B748A5D

Q24628361-0DECAD8F-7E13-485C-91AD-1D87742CE12C

Q24628361-0EC740C1-8886-4BA3-91CE-5AA1EC018DDB

Q24628361-0FD186F1-BB3B-440C-90E3-BA0FA62C3A02

Q24628361-1C7F86F7-318C-4197-B948-17A912B5AA00

Q24628361-2EB9C9B7-626F-4B0E-84A8-08EE4934A66F

Q24628361-3146CF61-58A6-4A2C-B031-A109429087DF

Q24628361-38AC43A9-E9DD-4313-87AA-2BC35DAC371C

P304

Q24628361-ECA00D66-C618-4C22-B5C7-424EBCEF1D4C

P31

Q24628361-25975F22-BD76-4B6B-A827-21081EBBC6E8

Q24628361-FBA52A81-B7ED-42BB-BB6D-10EEB1D1CC1F

P356

Q24628361-35BF8F84-AECA-4F4C-8E42-EBF90BA038DE

P407

Q24628361-4389A268-58D9-49BC-A05B-583B4236FCBB

P433

Q24628361-02121683-512B-4E2C-8B2B-65360A141EF4

P478

Q24628361-9CE36380-B622-484F-A453-95E096164F0E

P50

Q24628361-A1334E75-ED95-447C-B69B-BD32D50CF97D

Q24628361-C33BAAE7-2BD7-4C7A-BF9E-7012343495C0

Q24628361-E09439BD-15BE-4CDE-98AD-0EA2781061DD

P577

Q24628361-E92C0F2D-9E2F-4ED7-8B9D-CB227A30FF35

P5875

Q24628361-719A72A3-8206-40B9-BD45-8FCADD173D4D

P698

Q24628361-3635C009-B801-4EAF-BEC4-6D5DBD27E0A6

P921

Q24628361-231096C7-DB01-49D1-A1FA-C78820C765B9

Q24628361-70ECDD41-702D-4F13-BF3A-275835EC0D41

P932

Q24628361-76D6B03C-DF6A-4CB6-9B16-917D347985C5

P356

P1433

Canadian Medical Association Journal

P1476

Efficacy of statins for primar ...... vascular risk: a meta-analysis

@en

P2093

Anita Lloyd

http://www.w3.org/2001/XMLSchema#string

Braden Manns

http://www.w3.org/2001/XMLSchema#string

Brenda Hemmelgarn

http://www.w3.org/2001/XMLSchema#string

Finlay A McAlister

http://www.w3.org/2001/XMLSchema#string

Fiona Clement

http://www.w3.org/2001/XMLSchema#string

Jon Conly

http://www.w3.org/2001/XMLSchema#string

Scott Klarenbach

http://www.w3.org/2001/XMLSchema#string

P2860

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

Bias in meta-analysis detected by a simple, graphical test

Measuring inconsistency in meta-analyses

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

Meta-analysis in clinical trials

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

How should meta-regression analyses be undertaken and interpreted?

First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease

P304

E1189-202

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1503/CMAJ.101280

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

183

http://www.w3.org/2001/XMLSchema#string

P50

Marcello Tonelli

P577

2011-11-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51709080

http://www.w3.org/2001/XMLSchema#string

P698

21989464

http://www.w3.org/2001/XMLSchema#string

P921

Aparato circulatorio

P932

3216447

http://www.w3.org/2001/XMLSchema#string